Autism and Cell Therapy: Cord Blood and MSCs from the Umbilical Cord and Placenta
Date: May 2026
menu
Cell therapy for children with autism spectrum disorder (ASD) is one of the most common areas of inquiry at QR-clinic. The first cell therapy programs for children with ASD in Ukraine were carried out by our specialists back in 2010. Today, the clinic receives more than ten inquiries every month regarding the use of cord blood and mesenchymal stromal cells (MSCs) in children with ASD. This is related both to the growing prevalence of autism and to the increasing interest in cell therapy and regenerative medicine in neurology.
Autism, or Autism Spectrum Disorder (ASD), is a complex neurodevelopmental condition that affects social interaction, speech, behavior, and sensory perception.
Today, autism has no “magic pill,” and therapy usually includes a comprehensive approach: behavioral therapy, work with speech therapists and neuropsychologists, correction of associated disorders, and family support.
In recent years, cell therapy for autism has attracted increasing attention – primarily the use of cord blood and mesenchymal stromal cells (MSCs) from the umbilical cord and placenta. The reason for this interest is the potential effect of stem cells on neuroinflammation, immune dysregulation, and brain neuroplasticity.
At the same time, it is important to immediately emphasize the main point: cell therapy for autism remains an area of clinical research and individualized regenerative programs. It is not an officially approved “treatment for autism” in the USA, the EU, or Ukraine.
Why is cell therapy considered for autism at all
Modern studies show that most children with ASD may have:
- signs of chronic neuroinflammation
- impaired brain microglia function
- changes in immune response (autoimmune factor)
- disrupted interneuronal communication in the brain
- problems with brain neuroplasticity
That is why scientists began studying stem cells that may naturally regulate body functions and stimulate development in children with autism.
Which stem cells are used in autism
Cord blood
Umbilical Cord blood contains hematopoietic stem cells, immune cells, and a large number of signaling factors. Cord blood became one of the first types of cells studied in ASD, particularly at Duke University.
Main idea: stem cells and active factors from cord blood may influence neuroinflammation and support brain neuroplasticity, regulate immune system function, and reduce inflammation in the intestines. Over time, it was demonstrated that this therapy has a good safety profile, although it does not affect all patients.
In particular, the well-known Duke University ACT Trial demonstrated that the most pronounced effect was observed in some children aged 4–7 years with relatively preserved cognitive function.
Mesenchymal stromal cells (MSCs) from the umbilical cord and placenta
MSCs are currently considered one of the most promising areas of cell therapy. In neurological conditions, the following are most commonly used:
- MSCs from umbilical cord tissue (Wharton’s Jelly)
- MSCs from the placenta
- combined protocols together with cord blood
MSCs do not “replace neurons” on their own. Their effect is mainly associated with paracrine activity — the release of biologically active signaling molecules. Through this paracrine effect, MSCs influence neuroinflammation, neuroplasticity, and intercellular communication, and stimulate the body’s own recovery mechanisms.
What Does QR-clinic Offer for Children with ASD
QR-clinic is a center for cell therapy and regenerative medicine operating on the basis of the Hemafund biotechnology complex. We combine a clinical approach, our own laboratory infrastructure, and many years of experience working with stem cells.
For children with Autism Spectrum Disorder (ASD), our clinic offers:
- consultation with cell therapy specialists
- analysis of medical records and assessment of the appropriateness of the program
- individualized selection of the type of cellular product
- application of cord blood, MSCs from the umbilical cord, and placenta
- work with both autologous and donor cellular products
- selection of the administration method and therapy protocol
- clinical follow-up after cell administration
- coordination with rehabilitation specialists, speech therapists, and other healthcare professionals
Importantly, QR-clinic works in cooperation with the Hemafund biobank, which provides:
- testing of cellular products
- quality control at all stages
- proprietary cryologistics
- storage of cord blood and tissues
- preparation of the cellular product directly for clinical application
Each cell therapy program is selected individually. We take into account the child’s age, neurological condition, associated disorders, previous rehabilitation results, and the body’s response to therapy.
What age is considered the most promising for cell therapy
Most studies have been conducted in children:
- from 2 to 7 years old
- sometimes up to 12 years old
The best results are more often observed in younger children, which is logical due to higher brain neuroplasticity. This does not mean that older children or adolescents cannot benefit from treatment. However, at an early age, the brain has a significantly greater ability to adapt and form new neural connections.
What results can realistically be expected and when
This is a critically important point. Cell therapy is generally not capable of completely eliminating ASD manifestations. However, in most QR-clinic patients, socialization, concentration, and learning ability improve. Among the first effects parents often notice are improved sleep and nutrition, the appearance of pointing gestures and eye contact. Some children demonstrate progress in speech and communication.
Clinical programs most commonly evaluate:
- improvement in eye contact
- improvement in concentration
- reduction in hyperactivity
- improvement in speech
- reduction in sensory overload
- improvement in sleep
- improvement in learning and interaction with other people
The results of cell therapy are evaluated over the course of a year after treatment. During the course of cell therapy, it may be reasonable to adjust the treatment protocol — the type and dosage of stem cells, as well as the administration method.
In some children, the effect may be minimal or absent, and this should also be taken into account when planning cell therapy.
Route of stem cell administration, cell dosage, and frequency of therapy
The treatment protocol for each patient is selected individually by the physician, taking into account the patient’s age, condition, and the body’s response to cell therapy.
The recommended course consists of 2–3 administrations with intervals of 3–6 months between cell product administrations.
Cord blood cells are administered intravenously. Mesenchymal stromal cells from the umbilical cord or placenta can be administered intravenously, intramuscularly, as well as locally in associated orthopedic or neurological conditions — into the affected area, intrathecally (into the spine), parabulbarly (eye area), or into the joints. Some therapies require anesthesia or pain management.
All these administration methods in our clinic are performed only by experienced specialized physicians.
How to best prepare for cell therapy?
Before the program, it is usually recommended that the child be examined by a pediatrician, neurologist, child psychiatrist, and geneticist. An assessment of genetic and behavioral disorders and associated conditions should also be obtained.
Stem cells do not distinguish diagnoses; they help reduce symptoms and improve the child’s health condition. However, proper examination helps evaluate changes and introduce additional treatment or physiotherapy if needed.
During the initial consultation, our specialist collects medical history and refers the patient for additional evaluation if there is insufficient information or if doubts arise regarding the choice of treatment protocol.
Parents should follow the doctor’s recommendations for one year after cell administration.
It is undesirable to perform therapy during acute infections, poisoning, or active severe inflammation. Cell therapy is prescribed with caution in children with uncontrolled epilepsy.
How can the effect of cell therapy in children with autism be enhanced?
One of the important points is the child’s continued rehabilitation. We have noticed that better results are achieved in children who continue systematic rehabilitation while avoiding negative pressure and overload. More intensive rehabilitation methods (hardware-based) are better postponed for a month to avoid overloading the child’s brain. It is recommended to continue working with a speech therapist and psychologist, diversify sensory integration, and try introducing new foods. Sometimes after cell therapy, even a simple trip to the seaside or the appearance of new people in the child’s environment leads to remarkable developmental progress.
Cell therapy is not a replacement for rehabilitation, but rather a potential enhancement of the brain’s ability to learn and adapt.
A common question: what is better, autologous or donor cells?
In the treatment of children with neurological conditions, both autologous and donor stem cells from cord blood, umbilical cord, or placenta are used. The purpose of cell administration is not to replace the child’s bone marrow, but to influence the body’s own recovery potential through the paracrine effect. Administered cells do not integrate into tissues for a long time. Their main effect is associated with short-term paracrine and immunomodulatory activity. That is why the treatment is considered safe, since even donor cells do not alter the child’s genetics and do not form independent cellular growth in the body. The main requirement for therapy is that the cells are collected after the birth of a healthy child, have no infectious risk, and are properly tested and prepared for the production of the cellular product.
The quality of cell products, the ability to control all stages, and proprietary logistics to the clinic are advantages of the Hemafund biotechnology complex, which supplies our patients with cellular products.
If the family has preserved their own stem cells from cord blood or umbilical cord tissue in a biobank and they are suitable for a child with autism, therapy is started specifically with the family’s own material.
Advantages of a cellular product from an autologous deposit:
- perfect compatibility
- treatment cost
Donor mesenchymal stromal cells (MSCs) have high immune tolerance and therefore do not require matching by blood group or Rh factor. This material is most commonly used in donor programs.
Main conclusions: what modern science says
Today, studies of cord blood and MSCs in ASD appear promising. More than 20 years of experience have already been accumulated, but the evidence base is still developing.
What can already be said:
- therapy generally demonstrates a good safety profile
- positive changes are observed in most children
- early age appears to be the most promising
- umbilical cord MSCs and cord blood are considered the most promising for cell therapy
- the result strongly depends on the individual characteristics of the child
- cell therapy should be part of a comprehensive program
Main studies and sources
Request
consultation
Just fill the application and one of our specialists will contact you by e-mail, phone, or any other convenient way for you. We will be happy to answer all your questions and provide the necessary information.
